<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514657</url>
  </required_header>
  <id_info>
    <org_study_id>KCB-1D-01</org_study_id>
    <nct_id>NCT00514657</nct_id>
  </id_info>
  <brief_title>Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2</brief_title>
  <official_title>Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2 (Randomised Controlled Phase II Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaken Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaken Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present clinical trial clarified that basic fibroblast growth factor-2 (FGF-2) can induce
      regeneration of periodontal tissue lost by progression of periodontitis and evaluated the
      safety of such induction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of increase in alveolar bone height</measure>
    <time_frame>36 weeks after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical attachment level (CAL) regained</measure>
    <time_frame>36 weeks after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time course of rate of increase in alveolar bone height</measure>
    <time_frame>within 36 weeks after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time course of CAL regained</measure>
    <time_frame>within 36 weeks after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the other periodontal inspections (PD, BOP, GI etc.)</measure>
    <time_frame>within 36 weeks after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose (0.03 %)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium dose (0.1 %)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose (0.3 %)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)</intervention_name>
    <arm_group_label>P</arm_group_label>
    <arm_group_label>L</arm_group_label>
    <arm_group_label>M</arm_group_label>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed as 2- or 3-walled vertical intrabony defect &gt;=3 mm deep from the top of the
             remaining alveolar bone

          -  with mobility of the tooth of degree 2 or less

          -  with width of attached gingiva appropriate for Guided Tissue Regeneration

        Exclusion Criteria:

          -  concomitant administration of adrenal cortical steroid within 4 wks after the surgery

          -  administeration of calcium antagonist during the 4 weeks preceding administration of
             the investigational drug

          -  coexisting malignant tumour or history of the same

          -  coexisting diabetes (HbA1C &gt;= 6.5%)

          -  an extremely poor nutritional condition (serum albumin concentration &lt;2 g/dL)

          -  pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Makoto Tamura, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Kaken Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <last_update_submitted>August 9, 2007</last_update_submitted>
  <last_update_submitted_qc>August 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

